Optimising your outsourcing strategy14. 5. 2018
The European pharmaceutical market is currently the fifth largest market in the continent, enjoying steady growth and regulatory progression.
A Q&A with Contract Pharma: developing long-term partnerships when outsourcing22. 1. 2018
Outsourcing relationships have evolved over the last ten years. As companies refocus their in-house talent on their core business areas, this is driving the need for flexible and agile partners.
Formulation development: what could 2018 bring?22. 1. 2018
Each year brings new advancements and challenges in formulation development. In this Q&A with CPhI Online, Dr Beata Vladovicova, R&D manager at Saneca Pharma discusses what we can expect in the year to come.
Moving forward with controlled drug development22. 1. 2018
Beata Vladovivca, R&D Manager for Saneca Pharma talks to Innovations in Pharmaceutical Technology (IPT) about the latest advancements in controlled drug delivery methods, as part of a roundtable with other industry experts.
Whitepaper: The advantages and challenges of extrusion-spheronisation for pelletisation13. 6. 2017
Pelletisation can offer considerable advantages when it comes to drug delivery, particularly for controlled or delayed release of oral formulations. It can also reduce the risk of dose dumping, adverse side effects and irritation in the gastro-intestinal (GI) tract.
Contract manufacturing roundtable: part two9. 6. 2017
CDMOs are operating in an increasingly competitive marketplace, with new challenges emerging as a result of more complex pharmaceutical products entering the supply chain, evolving patient needs and regulatory changes.
Contract manufacturing roundtable: part one25. 5. 2017
The contract manufacturing landscape has changed drastically over the last ten years, with consolidation, increasing price pressures and evolving customer expectations impacting the way that services are delivered.
Advancements in extrusion-spheronisation4. 5. 2017
In recent years, pellets have gained considerable popularity as multi-particulate delivery systems owing to an array of benefits such as, more even and predictable distribution of the active pharmaceutical ingredient (API), the possibility of delivering multiple APIs in one dose, reduced potency and a lowered risk of side effects for the patient.
Central and Eastern European CMOs – the go-to choice for pharmaceutical outsourcing18. 4. 2017
The European pharmaceutical industry has grown exponentially over the last ten years. As a result, pharmaceutical manufacturers have faced a number of challenges as droughts, escalating costs, downward price pressure from governments and the need for faster turnaround times to bring new drugs to the market.
Did our portfolio meet your needs? Let´s discuss starting business with us.Contact us